[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567500":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":41,"locations":47,"responsibleParty":65,"collaborators":67,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":76,"sex":82,"minAge":83,"maxAge":10,"enrollmentInfo":84,"targetDuration":10,"studyType":87,"phases":10,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Gout patients treated according to a Treat-to-Dissolve strategy",null,"Patients initiated with ULT (urate target less than 40 mg\u002FL), and followed every 6 months with Ultrasound until complete urate dissolution",[13,14,15,16,17],"Diagnostic Test: Standard X-Rays","Diagnostic Test: Ultrasound","Diagnostic Test: DECT of feet","Biological: DNA sample","Biological: Serum collection",[19,24,28,32,37],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","Standard X-Rays","\\- Standard X-Rays: feet (Month 0)",[9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"Ultrasound","\\- Ultrasound (score 0-24): assessment for DC (Double Contour) sign (0-3), aggregates (0-3), tophi (0-3) at MTP1s (first metatarsophalangeal joints) and DC sign (0-3) at both knees, according to the OMERACT, every 6 months until complete dissolution of urate deposits.",[9],{"type":20,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"DECT of feet","DECT of feet: in tophaceous patients only (Month 0, Month 24)",[9],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":10},"BIOLOGICAL","DNA sample","DNA will be collected at Month 0",[9],{"type":33,"name":38,"description":39,"armGroupLabels":40,"otherNames":10},"Serum collection","\\- Serum will be collected at Month 0, Month 6, Month 12, Month 18, Month 24 , Month 36 and Month 48. For OMICs and epigenetic studies: Month 0, Month 6, Month 24 and Month 36.",[9],[42],{"name":43,"role":44,"phone":45,"phoneExt":10,"email":46},"Pascal RICHETTE, PR","CONTACT","0149956314","pascal.richette@aphp.fr",[48],{"facility":49,"status":50,"city":51,"state":10,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"APHP, Lariboisière Hospital, Rheumatology departement","RECRUITING","Paris","75010","France","FR",{"type":56,"coordinates":57},"Point",[58,59],2.3488,48.85341,{"lat":59,"lon":58},[62],{"name":63,"role":44,"phone":64,"phoneExt":10,"email":46},"Pr Richette pascal","0033149956314",{"type":66,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[68,71],{"name":69,"class":70},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"name":72,"class":73},"ART VIGGO Association for Research","UNKNOWN","100567500","time-required-to-dissolve-urate-deposits-100567500",false,"NCT06669000","Time Required to Dissolve Urate Deposits","Time Required to Dissolve Urate Deposits in Patients With Gout","ReViGoRe 40","Inclusion Criteria:\n\n* Age over 18 years\n* Gout according to the ACR\u002FEular 2015 criteria\n* SUA levels greater than 60 mg\u002FL\n* US score (MTP1s, knees) ≥2\u002F24\n* Informed consent Dated and signed voluntarily\n\nExclusion Criteria:\n\n* Ongoing urate lowering therapy\n* Severe and uncontrolled diseases such as cancer, cardiovascular or neurovegetative diseases\n* Pregnant or breast-feeding women\n* No affiliation to the French National Social Security System","ALL","18 Years",{"count":85,"type":86},250,"ESTIMATED","OBSERVATIONAL","Gout is characterized by episodes of acute arthritis of the lower limbs due to intermittent activation of innate immunity in the joints where urate crystals have formed. These crystals occur when serum urate (SUA) levels have been above 70 mg\u002FL for many years. They can be dissolved by lowering SUA levels to at least 60 mg\u002FL (treat-to-target - T2T - strategy). Once the crystals are dissolved, patients are no longer symptomatic and are considered to be in remission (treat-to-dissolve - T2D - strategy).\n\nThe presence of crystals and their dissolution during treatment can be monitored by repeated ultrasound (US) scans of the feet and knees.\n\nThe time required for complete dissolution varies from patient to patient. ReViGore40 is a cohort designed to i) determine the time to complete dissolution of urate deposits in joints when SUA levels are maintained below 40 mg\u002FL, ii) determine the factors (clinical, biological, genetic) associated with the time required for complete dissolution of urate deposits within joints.",[90],"Gout",[90,92,93,94,95,25,96,97],"Flares","Tophi","Urate levels","Urate deposits","Allopurinol","Febuxostat","2026-02-17",{"date":100,"type":101},"2026-02-19","ACTUAL",{"date":103,"type":101},"2024-09-24",{"date":105,"type":86},"2032-09-24",{"name":5,"class":6},1]